ASND Ascendis Pharma A/S Insider Trading

CFO Scott Thomas Smith purchases 100 ASND shares at $219.00; stock down 10.5% in 30 days

CFO Scott Thomas Smith acquired 100 shares of Ascendis Pharma at $219.00 on 2026-06-02, increasing his holdings from 4,267 to 4,367 shares. The transaction occurred as the stock has declined 10.5% over the past 30 days and is trading 13.0% below its 52-week high of $250.74. This modest insider buy by a senior financial officer may indicate comfort with the current valuation, though the modest share count—a 2.3% increase in his holdings—and the broader recent price weakness suggest this is not a material accumulation signal.

CFO Scott Thomas Smith purchases 250 ASND shares at $223.32; stock now -13.0% from 52-week high

Scott Thomas Smith, EVP & Chief Financial Officer, purchased 250 shares at $223.32 on 2026-05-29, increasing his holdings from 4,017 to 4,267 shares (a +6.2% increase). The current price of $218.06 represents a -13.0% decline from the 52-week high of $250.74, and the stock has fallen -10.5% over the prior 30 days. The transaction occurred as the stock faced downward momentum across both the recent month and quarter (-3.5% over 90 days), providing context for an insider purchase at a depressed price level relative to recent peaks.

ASND Director Jean Jacques Bienaime bought 500 shares for $111,562.00 across 3 trades at $223.12 blended average on 2026-05-29.

Jean Jacques Bienaime, a Director, executed 3 separate purchases totaling 500 shares for $111,562.00 at a blended average price of $223.12 on 2026-05-29, increasing his holdings from 400 to 900 shares (+125.0%). The purchases occurred when the stock was trading at prices above the current price of $218.06, and the stock has declined -10.5% over the prior 30 days and -3.5% over the prior 90 days. Historically, Bienaime's 10 prior buys across all tickers have averaged +1.3% 30-day returns and -5.2% 90-day returns with a 40.00% win rate, suggesting a mixed track record on buy timing.

Director Jean Jacques Bienaime purchases 400 ASND shares for $95,120.50 total at $237.80 avg; stock down -10.5% in 30 days.

Director Jean Jacques Bienaime made 2 separate purchases totaling 400 shares for $95,120.50 on 2026-05-26, at an average price of $237.80 per share, increasing his holdings from 0 to 400 shares. The current price of $218.06 sits -13.0% below the 52-week high of $250.74, with the stock down -10.5% over the past 30 days. Across his prior open-market activity at all tickers, this director's 10 prior buys posted an average 30-day return of +1.3% but a 90-day return of -5.2% with a 40.00% win rate, indicating a mixed historical pattern that does not clearly predict the outcome of this new accumulation.

Officer Flemming Steen Jensen sells entire 19,460-share position for $4.6M, first open-market sale in 3-year window.

Flemming Steen Jensen, an officer at Ascendis Pharma, has exited his complete shareholding through a single open-market sale, raising $4.6M. This marks his first open-market sale in the past three years, making it a notable departure from his prior inactivity on the trading front. The sale occurred when the stock was trading near its recent range—below the 52-week high but above the 52-week low—providing no obvious signal of market timing advantage. While the size of this transaction is material in absolute terms, the absence of any prior insider trading activity (buying or selling) in the historical window leaves little context for interpreting his intent: this could reflect a one-time liquidity event, a portfolio shift, or departure planning, but the data alone does not establish which.